Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Daniel T. Dransfield, Ph.D. as vice president and head of translational medicine. Dr. Dransfield, formerly vice president of discovery research and translational medicine at ArQule, Inc., brings more than 20 years of drug development and research experience to Tokai.